Symbiotec Pharmalab IPO: ₹1,757 Cr RHP Details & Dates | DA
Indore-based research-driven active pharmaceutical ingredient (API) manufacturer and biotechnology contract development specialist Symbiotec Pharmalab Limited has officially filed its Red Herring Prospectus (RHP) dated 19 August 2026 with the Registrar of Companies (RoC) and the Securities and Exchange Board of India (SEBI) for an Initial Public Offering aggregating up to ₹1,757.00 Crore. Founded in 2002 by Anil Satwani, the company operates dedicated USFDA-, PMDA Japan-, and WHO-GMP-inspected fermentation and chemical synthesis manufacturing facilities in Pithampur SEZ and Rau, specializing in high-barrier steroidal APIs including corticosteroids and sex hormone derivatives. The public issue is structured with a statutory price band of ₹938.00 to ₹988.00 per equity share (face value ₹5.00), comprising a primary Fresh Issue of ₹150.00 Crore alongside an Offer for Sale (OFS) of up to 16,268,760 equity shares (worth approximately ₹1,607.00 Crore) by promoters and institutional private equity selling shareholders (including Actis-affiliated investment vehicles). Bidding for anchor investors takes place on Friday, 21 August 2026, followed by the public subscription window opening on Monday, 24 August 2026, and closing on Thursday, 27 August 2026, ahead of mainboard listing on BSE and NSE scheduled for Tuesday, 1 September 2026.
1. Symbiotec Pharmalab IPO: Key Issue Parameters & Capital Structure
Indore-headquartered research-driven active pharmaceutical ingredient (API) manufacturer and biotechnology contract development organization (CDMO) Symbiotec Pharmalab Limited has officially registered its Red Herring Prospectus (RHP) dated 19 August 2026 with the Registrar of Companies (RoC) and the Securities and Exchange Board of India (SEBI).
The ₹1,757.00 Crore mainboard public offering is structured under the standard SEBI ICDR framework:
| Core Issue Parameter | Official Terms (RHP Filed with SEBI) | Regulatory Verification Status |
|---|---|---|
| Issuer Corporate Entity | Symbiotec Pharmalab Limited (CIN: U24231MP2002PLC015095) | CONFIRMED (SEBI RHP / ROC Gwalior) |
| Statutory Filing Milestone | Red Herring Prospectus (RHP) Registered on 19 August 2026 | CONFIRMED (SEBI Public Issues Archive) |
| Issue Segment & Architecture | 100% Book Built Mainboard Issue | CONFIRMED (SEBI ICDR Regulations, 2018) |
| Public Bidding Window | Opens: 24 August 2026 | Closes: 27 August 2026 | CONFIRMED (Official Stock Exchange Circular) |
| Statutory Price Band | ₹938.00 to ₹988.00 per Equity Share (Face Value ₹5.00) | CONFIRMED (Floor & Cap Price Notice) |
| Market Bid Lot Size | 15 Equity Shares (and multiples of 15 thereafter) | CONFIRMED (Stock Exchange Circular) |
| Minimum Retail Commitment | ₹14,820 (15 Shares × ₹988 Upper Cap) | CONFIRMED (Mandatory UPI ASBA Lien) |
| Total Issue Sizing | Up to ₹1,757.00 Crore | CONFIRMED (Offer Document Section IV) |
| Fresh Issue Component | ₹150.00 Crore (Primary Capital Infusion) | CONFIRMED (Expansion & Debt Repayment) |
| Offer for Sale (OFS) | Up to 16,268,760 Equity Shares (~₹1,607.00 Cr) | CONFIRMED (Promoter & Private Equity Tranches) |
| Designated Registrar | MUFG Intime India Private Limited (formerly Link Intime) | CONFIRMED (Registrar Allotment Module) |
| Book Running Lead Managers | JM Financial, Avendus Capital, Motilal Oswal, Nomura | CONFIRMED (Lead Underwriting Syndicate) |
2. Shareholding Pattern & Private Equity Selling Shareholder Tranches
The Offer for Sale (OFS) component of approximately ₹1,607.00 Crore allows private equity investors and promoter entities to monetize their shareholdings:
| Selling Shareholder Name | Shareholder Category | Shares Offered in OFS | Pre-Issue Holding (%) | Post-Issue Dilution Impact |
|---|---|---|---|---|
| Promoter Selling Entities (Anil Satwani & Family) | Promoter & Promoter Group | 2,500,000 Shares | 48.50% | Partial profit booking; retains long-term control |
| Private Equity Investor (Actis & Associated Funds) | Institutional Private Equity | 13,768,760 Shares | 42.10% | Substantial exit of early-stage private equity funding |
| Total Secondary OFS Tranche | Promoters & Private Equity | 16,268,760 Shares | 90.60% | ~₹1,607.00 Crore at Upper Cap of ₹988 |
3. Price Band, Lot Size, and Minimum Investment Sizing
Retail individual investors and institutional non-institutional investors (NII) can bid across specific categories under SEBI ICDR regulations:
| Application Bidding Category | Lots Applied | Total Shares | Minimum Commitment (₹ at Cut-off) | Maximum Commitment (₹ at Cut-off) |
|---|---|---|---|---|
| Retail Minimum (1 Lot) | 1 Lot | 15 Shares | ₹14,820 | ₹14,820 |
| Retail Maximum (13 Lots) | 13 Lots | 195 Shares | ₹1,92,660 | ₹1,92,660 |
| Small HNI Minimum (14 Lots) | 14 Lots | 210 Shares | ₹2,07,480 | ₹2,07,480 |
| Small HNI Maximum (67 Lots) | 67 Lots | 1,005 Shares | ₹9,92,940 | ₹9,92,940 |
| Big HNI Minimum (68 Lots) | 68 Lots | 1,020 Shares | ₹10,07,760 | Subject to investor bidding scale |
4. Steroid Chemistry Moat: Corticosteroids, Hormones & Biotechnology
Symbiotec Pharmalab has developed a specialized technological moat in complex steroidal chemical synthesis and fermentation:
| API Therapeutic Class | Key Commercial Molecules | Technical Regulatory Registrations | Revenue Share (%) |
|---|---|---|---|
| Corticosteroids | Hydrocortisone, Prednisolone, Methylprednisolone, Dexamethasone, Budesonide | Active Drug Master Files (DMFs) with USFDA, EDQM, and PMDA Japan | ~52.0% |
| Sex Hormones & Steroid Derivatives | Estrogens, Progestins, Testosterone Intermediates, Norethisterone | CEP filings across Europe and specialized generic filings globally | ~26.0% |
| Steroidal Biotechnology Intermediates | Fermentation-derived biological precursors from basic phytosterols | Dedicated proprietary biotransformation bioreactor contracts | ~14.0% |
| Other Specialized APIs & Formulations | Anti-fungals, veterinary APIs, and specialized dermatological compounds | Customized CDMO synthesis contracts with global pharmaceutical innovators | ~8.0% |
5. Regulatory Compliance & USFDA Clean-Room Manufacturing Scale
The company's operational infrastructure conforms to stringent international regulatory standards:
- Pithampur SEZ & Rau Facilities: Operates advanced manufacturing, chemical synthesis, and biological fermentation units located near Indore, Madhya Pradesh.
- Global Regulatory Approvals: Facilities undergo periodic statutory inspections by the **United States Food and Drug Administration (USFDA)**, **World Health Organization (WHO-GMP)**, **PMDA Japan**, and **European EDQM**.
- Export Orientation: Generates over **70% of consolidated operating revenues** from regulated export markets across North America, Europe, Latin America, and Asia-Pacific.
6. 3-Year Audited Financial Health & CDMO Operating Margins
Symbiotec Pharmalab's restated consolidated financial statements reflect steady top-line compounding and robust operating margins:
| Financial & Operating Indicator | FY 2023-24 (Audited) | FY 2024-25 (Audited) | FY 2025-26 (Audited RHP) | Growth Trajectory & Margins |
|---|---|---|---|---|
| Revenue from Operations | ₹584.20 Cr | ₹712.50 Cr | ₹878.40 Cr | Compounded at ~22.6% CAGR on global API demand |
| Operating EBITDA | ₹152.10 Cr | ₹192.40 Cr | ₹242.50 Cr | Expanded 59.4% across 2 years with chemical scale |
| Operating EBITDA Margin (%) | 26.03% | 27.00% | 27.61% | High margins sustained by complex steroidal chemistry |
| Restated Net Profit (PAT) | ₹92.40 Cr | ₹121.80 Cr | ₹158.20 Cr | Profit compounded at ~30.8% CAGR on efficient tax planning |
| Export Revenue Share (%) | 68.40% | 71.20% | 73.50% | High-margin regulated market focus in US, EU, and Japan |
7. Strategic Competitive Strengths vs. Pharmaceutical Regulatory Risks
Investors analyzing Symbiotec Pharmalab should weigh its technical expertise against regulatory compliance scrutiny:
Institutional Competitive Strengths
- High Barrier Steroidal Chemistry: Niche expertise in complex biotransformation and fermentation.
- Regulated Global Markets: 73%+ export revenues backed by USFDA and EDQM regulatory compliance.
- Healthy Financial Profile: ~27.6% EBITDA margins and ₹158 Cr net profit in FY26.
- Long-Standing Innovator Relationships: Multi-year supply contracts with leading generic drugmakers.
Inherent Business & Sector Risks
- USFDA Regulatory Scrutiny: Any inspection observations (Form 483, warning letters) can disrupt shipments.
- Secondary OFS Dilution: OFS represents ₹1,607.00 Crore of the total ₹1,757.00 Crore issue size.
- Raw Material Price Fluctuations: Dependence on sterol starting materials and chemical reagents.
- Customer Concentration: Top 10 pharmaceutical clients account for a meaningful portion of revenue.
8. Grey Market Premium (GMP) Trends & Post-Issue Settlement Timetable
As of 20 August 2026, unofficial market indicators reflect an estimated opening Grey Market Premium (GMP) of ₹140 to ₹155 per share (~15% to 16% premium over the ₹988 upper price band). GMP represents unregulated over-the-counter quotes and does not guarantee listing performance.
The official post-issue timetable proceeds as follows:
| Event Milestone | Scheduled Date (2026) | Operational Description & Investor Guidelines |
|---|---|---|
| Anchor Investor Bidding Date | Friday, 21 August 2026 | Institutional anchor book allocation ahead of public opening |
| Issue Opens for Public Bidding | Monday, 24 August 2026 | 10:00 AM IST commencement of electronic order books on BSE & NSE |
| Issue Closes (Final Bidding Day) | Thursday, 27 August 2026 | 5:00 PM IST cut-off for UPI ASBA mandate authorizations |
| Basis of Allotment Finalisation | Friday, 28 August 2026 | MUFG Intime India reconciles bids and executes computerized lottery draw |
| Initiation of Refunds & Mandate Unblocking | Monday, 31 August 2026 | Sponsor banks release fund liens for unsuccessful applicants |
| Credit of Equity Shares to Demat | Monday, 31 August 2026 | CDSL & NSDL credit allotted shares directly to demat accounts |
| Tentative Mainboard Listing | Tuesday, 1 September 2026 | Trading commences on BSE and NSE Mainboard under T+3 settlement |
9. Step-by-Step Investor Application Guide via UPI ASBA
Retail investors can bid for Symbiotec Pharmalab shares using standard UPI ASBA protocols:
- Log in to Your Trading Platform: Open your registered broker portal (Upstox, Zerodha, Groww, Angel One) and navigate to the IPO section.
- Select Symbiotec Pharmalab IPO: Choose the issue from the list of active public offers.
- Enter Bid Specifications: Specify the number of lots (e.g., 1 lot = 15 shares) and ensure the "Cut-off Price" box (₹988) is checked.
- Enter Valid UPI ID: Submit your UPI ID linked to your primary bank account with sufficient unencumbered funds.
- Approve Mandate Request: Open your UPI mobile application (BHIM, Google Pay, PhonePe, Paytm) and approve the mandate authorization request before 5:00 PM IST.
10. Statutory Regulatory Disclosures & Official Filing References
All operational metrics, financial statistics, issue structures, and regulatory disclosures cited in this guide are verified against official filings:
- SEBI Public Issues Offer Document Archive: Symbiotec Pharmalab Limited Red Herring Prospectus (RHP) .
- Bombay Stock Exchange (BSE): BSE Mainboard Public Issues Portal .
- National Stock Exchange of India (NSE): NSE Mainboard Public Issues Console .
- Designated Registrar Console: MUFG Intime India IPO Application & Allotment Module .
- Corporate Governance Portal: Symbiotec Pharmalab Limited Official Portal .
Frequently Asked Questions (Institutional FAQ Desk)
Statutory Regulatory Disclosures & Editorial Standards
Source Attribution: Information published on Digital Arthalaya is curated from publicly filed Draft Red Herring Prospectuses (DRHP), Red Herring Prospectuses (RHP), Price Band Advertisements, and Official Stock Exchange (BSE/NSE) notifications.
Non-Advisory Mandate & Risk Warning: Digital Arthalaya is strictly an independent financial education portal and is not a SEBI-registered investment advisor or stock broker. IPO bidding and equity trading involve market risk, including potential loss of principal. Readers must conduct their own independent due diligence and read all offer documents carefully before making investment commitments.